These findings highlight the therapeutic potential of targeting the TGF-β/Smad pathway and enhancing FBLN1 expression to alleviate ARDS-associated oxidative stress and ferroptosis. This evidence concerns the gene FBLN1 and acute respiratory distress syndrome.